April 10 has quietly become one of the most closely watched dates on Wall Street’s calendar, and for investors with any exposure to Eli Lilly, the significance of that day is hard to overstate. That is when the U.S. Food and Drug Administration is expected to deliver its verdict on Orforglipron, the company’s oral weight-loss […]

The postEli Lilly stock hinges on one critical FDA decisionappeared first onRolling Out.